基于纳米载体的抗肿瘤药物研究进展  

The Research Progress of Anti-tumor Nanodrugs Based on Nanocarriers

作　　者：代献花 张廷英 黄勇[3] 陶万茹 张莉[1] 李威[3] 梁蓓蓓 DAI Xianhua;ZHANG Tingying;HUANG Yong;TAO Wanru;ZHANG Li;LI Wei;LIANG Beibei(Shanghai University of Traditional Chinese Medicine,Shanghai,201203,China;Shanghai Key Laboratory for Molecular Imaging,College of Pharmacy,Shanghai University of Medicine/Health Sciences,Shanghai,201318,China;Laboratory of Nano Biomedicine,Naval Medical University(Second Military Medical University),Shanghai,200433,China;School of Medical Instrument and Food Engineering,University of Shanghai for Science and Technology,Shanghai,200093,China)

机构地区：[1]上海中医药大学,上海201203 [2]上海健康医学院药学院/上海健康医学院分子影像重点实验室,上海201318 [3]海军军医大学(第二军医大学)纳米医学研究室,上海200433 [4]上海理工大学医疗器械与食品学院,上海200093

出　　处：《肿瘤药学》2019年第6期850-854,共5页Anti-Tumor Pharmacy

基　　金：海军军医大学青年启动基金(2018QN03)

摘　　要：纳米技术的发展为恶性肿瘤的治疗提供了一种新的思路。近年来,纳米药物在肿瘤靶向递送和提高恶性肿瘤治疗效果等方面显示出较大的研发前景,一些纳米药物已成功应用于恶性肿瘤的临床治疗。本文就抗肿瘤纳米药物的特征以及处于临床转化阶段的抗肿瘤纳米药物的优势和不足进行归纳总结,并对一些新型的针对肿瘤微环境的纳米药物进行介绍。The development of nanotechnology provides a new strategy for the cancer therapy.In recent years,nanodrugs have shown great progess in its targeted delivery system and high-effective function to defeat cancer.Some of them have been applied to clinical cancer treatment.The article summarizes the characteristics of anti-tumor nanodrugs and presents an overview of advantages and disadvantages of some clinical traslational anti-tumor nanodrugs and some novel nanodrugs aiming at the tumor microenvironment.

关 键 词：恶性肿瘤 纳米药物 肿瘤微环境 

分 类 号：R9[医药卫生—药学]